Subsequent Treatments After Progression on Cyclin-Dependent Kinase 4/6 Inhibitors: A Review of the Evidence and a Real-World Data Perspective From Portuguese Hospitals.

Cureus · 2026 · PMC13270884 · PMID 42311745

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Abemaciclib also demonstrated an advantage in PFS (29.0 versus 14.8 months; HR, 0.54; 95% CI, 0.43-0.67) and OS (66.8 versus 53.7 months; HR, 0.80; 95% CI, 0.64-1.0), although the OS did not reach statistical significance in the MONARCH-3 trial [ 10 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.